Literature DB >> 30168589

Hepatitis E seroprevalence in the United States: Results for immunoglobulins IGG and IGM.

Causenge Cangin1, Brian Focht2, Randall Harris3, Julie A Strunk4.   

Abstract

BACKGROUND: Previous research identified a decline in hepatitis E virus (HEV) seroprevalence in US in 1988-1994 and 2009-2010. We investigated most recent HEV epidemiology.
METHOD: Using a nationally representative sample (7656 persons in the National Health and Nutrition Examination Survey [NHANES] 2013-2014 and 7124 persons in NHANES 2015-2016), we compared the weighted seroprevalence of HEV (immunoglobulin G [IgG]/immunoglobulin M [IgM]) among people from the US (aged ≧ 6 years) between these two time periods. Sampling-weighted multivariate logistic regression models were used to identify factors associated with HEV seropositivity.
RESULTS: The median participant age was 37 years (interquartile range = 17-58 years); 51.17% of them were female. Among US-born individuals, HEV seropositivity (IgG/IgM) increased from 4.5% (95% confidence interval [CI] = 3.5%-5.5%) in 2013-2014 to 8.1% (95%CI = 6.5%-9.7%) in 2015-2016. Recent HEV infection (IgM) has nearly doubled in all US-born people. For participants born in and outside of the US, the overall weighted HEV (IgG/IgM) seropositivity increased from 5% (95%CI = 3.9%-6.1%) during 2013-2014 to 7.7% (95%CI = 7.2%-10.5%) during 2015-2016. In "non-Hispanic Asian" females, HEV seropositivity (IgG/IgM) rose from 8.4% (95%CI = 5.6%-11.1%) during 2013-2014 to 20.7% (95%CI = 15.8%-25.7%) during 2015-2016. In "non-Hispanic Asian" males, HEV seropositivity (IgG/IgM) increased from 9.3% (95%CI = 6.9%-11.8%) during 2013-2014 to 16.8% (95%CI = 12.5%-21.2%) during 2015-2016. HEV (IgG/IgM) seropositivity was significantly associated with "non-Hispanic Asian" ethnicity (odds ratio [OR] = 1.69; CI = 1.12-2.56), female (OR = 1.2, CI = 1.06-1.38), and age (OR = 1.058, CI = 1.05-1.06). No clear etiologic agent was found.
CONCLUSION: The combined and strata-specific HEV weighted seroprevalence increased from 2013-2014 to 2015-2016. Although prior studies had found increasing age as the only significant factor associated with HEV, the attribute of "non-Hispanic Asian" had a stronger association with HEV seropositivity than the age factor alone.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  epidemiology; hepatitis E virus (HEV); immunoglobulin

Year:  2018        PMID: 30168589     DOI: 10.1002/jmv.25299

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Hepatitis E virus infects brain microvascular endothelial cells, crosses the blood-brain barrier, and invades the central nervous system.

Authors:  Debin Tian; Wen Li; C Lynn Heffron; Bo Wang; Hassan M Mahsoub; Harini Sooryanarain; Anna M Hassebroek; Sherrie Clark-Deener; Tanya LeRoith; Xiang-Jin Meng
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-07       Impact factor: 12.779

2.  Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis.

Authors:  Nathalie Verónica Fernández Villalobos; Barbora Kessel; Isti Rodiah; Jördis Jennifer Ott; Berit Lange; Gérard Krause
Journal:  PLoS One       Date:  2022-06-01       Impact factor: 3.752

Review 3.  Hepatitis E in immunocompromised individuals.

Authors:  Konstantinos Damiris; Mohamad Aghaie Meybodi; Mumtaz Niazi; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2022-03-27

4.  Low seroprevalence of hepatitis E on Reunion island.

Authors:  Patrick Gérardin; Vincent Porphyre; Anita Tsatoromila; Laurent Cuissard; Jean-Philippe Becquart; Karim Boussaid; Antoine Bertolotti; Florence Naze; Sandrine Picot; Laurent Filleul; Pablo Tortosa; Julien Jaubert; Vanina Guernier; Hervé Pascalis
Journal:  One Health       Date:  2019-10-23

Review 5.  Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature.

Authors:  Hang Liu; Ying Ma
Journal:  Brain Behav       Date:  2019-12-11       Impact factor: 2.708

6.  Seroprevalence of hepatitis E virus antibodies in adults and children from upstate New York: A cross-sectional study.

Authors:  Brittany L Kmush; Amelia M Lu; Taylor Spillane; Bryce Hruska; Brooks B Gump; Kestutis G Bendinskas
Journal:  PLoS One       Date:  2021-01-26       Impact factor: 3.240

Review 7.  From hepatitis A to E: A critical review of viral hepatitis.

Authors:  Daniel Castaneda; Adalberto Jose Gonzalez; Mohammad Alomari; Kanwarpreet Tandon; Xaralambos Bobby Zervos
Journal:  World J Gastroenterol       Date:  2021-04-28       Impact factor: 5.742

8.  Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients.

Authors:  Juozas Grigas; Maria Montoya; Evelina Simkute; Marius Buitkus; Ruta Zagrabskaite; Arnoldas Pautienius; Dainius Razukevicius; Laimas Virginijus Jonaitis; Gediminas Kiudelis; Jurgita Skieceviciene; Ruta Vaiciuniene; Asta Stankuviene; Inga Arune Bumblyte; Juozas Kupcinskas; Arunas Stankevicius
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

9.  Hepatitis E Infection in a Longitudinal Cohort of Hepatitis C Virus and HCV/HIV Coinfected Persons.

Authors:  Kenneth E Sherman; Shyam Kottilil; Susan D Rouster; Enass A Abdel-Hameed; Ceejay L Boyce; Heidi L Meeds; Norah Terrault; M Tarek Shata
Journal:  AIDS Res Hum Retroviruses       Date:  2021-05-10       Impact factor: 1.723

10.  Hepatitis E Virus Infection in a Northern Mexican City: A Cross-Sectional Seroprevalence Study.

Authors:  Cosme Alvarado-Esquivel; Ada Agustina Sandoval-Carrillo; José Manuel Salas-Pacheco; Elizabeth Irasema Antuna-Salcido; Karla Sujey Castro-Martínez; Diana Stephanie Ortiz-Montaño; Isabel Beristain-Garcia; Agar Ramos-Nevarez; Antonio Sifuentes-Alvarez; Elizabeth Rábago-Sánchez; Sandra Margarita Cerrillo-Soto; Edith Contreras-Cisneros
Journal:  Iran J Public Health       Date:  2021-01       Impact factor: 1.429

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.